SVB Leerink initiated coverage of Amryt Pharma PLC (NASDAQ:AMYT) with an “outperform” rating and price target of $22. Analyst Mani Foroohar, M.D., writes that Amryt’s model of acquiring niche commercial or near...
Maxim Group launched coverage of Amryt Pharma plc (NASDAQ, AIM:AMYT) with a “buy” rating and $27 price target. The stock closed at $13.84 on March 30. Amryt is a commercial rare disease company globally marketing...
SVB Leerink launched coverage of Amryt Pharma (NASDAQ:AMYT) with an “outperform” rating and $40 price target. The stock closed at $14.15 on Feb. 12. “Filsuvez is poised to be the first approved treatment for...